Bookmark
Forward
QuickView for Etretinate (compound)
PubChem
| Name: | Etretinate |
|---|---|
| PubChem Compound ID: | 3312 |
| Description: | An oral retinoid used in the treatment of keratotic genodermatosis, lichen planus, and psoriasis. Beneficial effects have also been claimed in the prophylaxis of epithelial neoplasia. The compound may be teratogenic. |
| Molecular formula: | C23H30O3 |
| Molecular weight: | 354.483 g/mol |
DrugBank
Identification
| Name: | Etretinate |
|---|---|
| Name (isomeric): | DB00926 |
| Drug Type: | small molecule |
| Description: | An oral retinoid used in the treatment of keratotic genodermatosis, lichen planus, and psoriasis. Beneficial effects have also been claimed in the prophylaxis of epithelial neoplasia. The compound may be teratogenic. |
| Brand: | Tegison, Tigason |
| Category: | Keratolytic Agents |
| CAS number: | 54350-48-0 |
Pharmacology
| Indication: | For the treatment of severe psoriasis in adults. |
|---|---|
| Pharmacology: |
The active metabolite responsible for etretinate's effects, acitretin, is a retinoid. Retinoids have a structure similar to vitamin A and are involved in the normal growth of skin cells. Acitretin works by inhibiting the excessive cell growth and keratinisation (process by which skin cells become thickened due to the deposition of a protein within ...
show more » |
| Mechanism of Action: | The mechanism of action of the active metabolite, acitretin, is unknown, however it is believed to work by targeting specific receptors (retinoid receptors) in the skin which help normalize the growth cycle of skin cells. |
| Absorption: | Absorbed in the small intestine. Studies in normal volunteers indicate that the absorption of etretinate is greater in patients consuming whole milk or a high-fat diet than in patients in a fasting state. |
| Protein binding: | More than 99% bound to plasma proteins, predominantly lipoproteins, whereas its active metabolite, acetretin (etretin), is predominantly bound to albumin. |
| Biotransformation: | Extensively metabolized, with significant first-pass metabolism to the pharmacologically active acid form. Subsequent metabolism results in the inactive 13-cis acid form, chain-shortened breakdown products, and conjugates that are ultimately excreted. |
| Half Life: | In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed. |
| Toxicity: | Symptoms of overdose include headache and vertigo. |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
Enzymes
Carriers
